Sriram Yennu

Dr. Sriram Yennu

University of Texas MD Anderson Cancer Center

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Sriram YennuSriram Yennu
Sriram Yennu
SFSusan Frisbee-Hume
Susan Frisbee-Hume
JPJ. Lynn Palmer
J. Lynn Palmer
MDMarvin O. Delgado-Guay
Marvin O. Delgado-Guay
JBJanet Bull
Janet Bull
EBEduardo Bruera
Eduardo Bruera
Purpose: Cancer-related fatigue (CRF) is the most common symptom in patients with advanced cancer. The primary objective of this prospective, randomized, double-blind, placebo-controlled study was to compare the effect of dexamethasone and placebo on CRF. Patients and Methods: Patients with advanced cancer with ≥ three CRF-related symptoms (ie, fatigue, pain, nausea, loss of appetite, depression, anxiety, or sleep disturbance) ≥ 4 of 10 on the Edmonton Symptom Assessment Scale (ESAS) were eligible. Patients were randomly assigned to either dexamethasone 4 mg or placebo orally twice per day for 14 days. The primary end point was change in the Functional Assessment of Chronic Illness–Fatigue (FACIT-F) subscale from baseline to day 15. Secondary outcomes included anorexia, anxiety, depression, and symptom distress scores. Results: A total of 84 patients were evaluable (dexamethasone, 43; placebo, 41). Mean (± standard deviation) improvement in the FACIT-F subscale at day 15 was significantly higher in the dexamethasone than in the placebo group (9 [± 10.3] v 3.1 [± 9.59]; P = .008). The improvement in FACIT-F total quality-of-life scores was also significantly better for the dexamethasone group at day 15 (P = .03). The mean differences in the ESAS physical distress scores at day 15 were significantly better for the dexamethasone group (P = .013, respectively). No differences were observed for ESAS overall symptom distress (P = .22) or psychological distress score (P = .76). Frequency of adverse effects was not significantly different between groups (41 of 62 v 44 of 58; P = .14). Conclusion: Dexamethasone is more effective than placebo in improving CRF and quality of life in patients with advanced cancer.

1 March 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
Sriram YennuSriram Yennu
Sriram Yennu
JAJoseph Arthur
Joseph Arthur
SRSuresh Reddy
Suresh Reddy
TETonya Edwards
Tonya Edwards
ZLZhanni Lu
Zhanni Lu
EBEduardo Bruera
Eduardo Bruera
Cancer pain is one of the most frequent and debilitating symptoms in patients with cancer.1-5 Opioids are the mainstay for cancer pain management. Currently, the use of opioids for cancer pain is suboptimally managed despite their need. Various contributing factors play a role in suboptimal use of opioids; these include limited education, variable access due to opioid shortages, and the need for opioid preauthorization, which is the result of the ongoing opioid epidemic in the US. The US government enacted restrictive legislation on opioid access, which indirectly affected clinical cancer pain management.1-5 Nonmedical opioid use (NMOU), ie, the use of opioids without a prescription or in ways other than medically prescribed, is common and may significantly affect cancer pain management. Nonmedical opioid use is trending to be one of the main concerns in pain management in the opioid crisis in patients both with and without cancer.6-14 In patients without cancer, NMOU is associated with negative health outcomes and overdose deaths.15-17 However, in oncology, the best practices for identifying and optimally managing NMOU are not yet clearly defined.12,18,19 Prior studies by our team and others were also able to establish the risk factors for NMOU in patients with cancer, but not all the patients with risk factors will be diagnosed with having NMOU behaviors, and some patients with no previous risk factors will engage in NMOU behaviors.20,21 Nonmedical opioid use behaviors may have long-term, devastating consequences for patients with cancer, including increased morbidity and mortality due to the possible development of substance use disorder, poor management of their cancer from lack of preventive and adherence practices to cancer treatments, and from the comorbidities (ie, mood disorders, insomnia) that accompany this condition.22-24 Hence, there is a need to develop optimal guidelines to screen and manage NMOU in patients with cancer.25,26 Nonmedical opioid use manifests in a range of behaviors, including early refill requests (self-escalation of opioids), resistance to prescription changes, opioid sharing between friends and family, requests for specific drugs, obtaining opioids from multiple physicians, using nonprescribed drugs, using opioids for nonprescribed indications (eg, anxiety, insomnia), family members expressing concern over the patient’s opioid use, discrepancy in pill counts, concurrent abuse of illicit drugs, impaired functioning per family or staff, prescription forgery, “lost or stolen” medications, and the selling or stealing of prescription drugs.19 One of the main aims of research on NMOU is to reduce the frequency of NMOU behaviors with interventions such as universal screening, reduced opioid exposure, and more intense follow-up of patients with elevated risk. Unfortunately, the absence of data on the frequency of NMOU behavior is the major barrier to conducting research on interventions to reduce NMOU. Additionally, there are no studies, to our knowledge, evaluating the independent predictors for NMOU behavior. Therefore, the aims of this study were to determine the overall frequency of NMOU behavior and to examine the independent predictors for NMOU behavior.

1 November 2017 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
KPKyung Ran Park
Kyung Ran Park
YLYong Chan Lee
Yong Chan Lee
YTYolanda D. Tseng
Yolanda D. Tseng
JLJay J. Liao
Jay J. Liao
SRSuresh Reddy
Suresh Reddy
Sriram YennuSriram Yennu
Sriram Yennu

1 October 2012 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
Sriram YennuSriram Yennu
Sriram Yennu
JWJie S. Willey
Jie S. Willey
JPJ. Lynn Palmer
J. Lynn Palmer
JAJulio Allo
Julio Allo
EFEgidio Del Fabbro
Egidio Del Fabbro
EBEduardo Bruera
Eduardo Bruera
Objectives: To determine the effects of thalidomide and placebo on anorexia-cachexia and its related symptoms, body composition, resting metabolic rate, and serum cytokines and their receptors in patients with advanced cancer. Methods: Included in the study were patients with advanced cancer with weight loss greater than 5% in 6 months and who reported anorexia, fatigue, and one of the following: anxiety, depression, or sleep disturbances. Patients on chemotherapy within 2 weeks prior or during the study were excluded from the study. Patients were randomly assigned to either 100 mg thalidomide or placebo once a day for 14 days. The Edmonton Symptom Assessment Scale (ESAS), Functional Assessment of Anorexia/Cachexia Therapy (FAACT), Functional Assessment of Cancer Illness Therapy (FACIT-F), Hospital Anxiety Depression Scale (HADS) Pittsburgh Sleep Quality Index (PSQI) were utilized, and in addition body composition, Resting Energy Expenditure (REE), and serum cytokine levels were assessed. Results: Of the 31 patients entered in the study, 15 were assigned to the thalidomide group and 16 to the placebo group. However only 21/31 patients were able to complete the study. Compared with their baseline values, both the thalidomide and the placebo groups showed significant reduction in cytokines. Tumor necrosis factor (TNF)-α (p=0.04) and its receptors TNFR1 (p=0.04), TNFR2 (p=0.04), and interleukin (IL)-8 (p=0.04) were statistically significant in the thalidomide group. In the placebo group, TNF-α (p=0.008), TNFR1 (p=0.005), TNFR2 (p=0.005), IL-RA (p=0.005), IL-6 (p=0.005), and IL-8 (p=0.005) were statistically significant. However, improvement in these symptoms and cytokine levels were not significantly different in the thalidomide group compared with the placebo group. None of the patients withdrew from the study because of toxicity of either thalidomide or placebo. Conclusions: Based on the poor accrual rate and attrition observed in this study, it is important that future research on thalidomide as a treatment for cancer-related anorexia-cachexia symptoms (ACS) in patients with advanced cancer use less stringent entry criteria and less exhaustive outcome measures.

13 December 2017 in Palliative Medicine
Verified
Journal Article
Closed access
Sriram YennuSriram Yennu
Sriram Yennu
LRLuis Fernando Rodrigues
Luis Fernando Rodrigues
OSOmar M Shamieh
Omar M Shamieh
CTColombe Tricou
Colombe Tricou
MFMarilène Filbet
Marilène Filbet
EBEduardo Bruera
Eduardo Bruera
Understanding patients’ decision control preferences is important in providing quality cancer care. Patients’ decisional control preference can be either active (patients prefer to make decisions themselves), shared (collaborative between patient, their physician, and/or family), or passive (patients prefer that the decisions are made by either the physician and/or their family). To determine the frequency and predictors of passive decision control preferences among advanced cancer patients. We also determined the concordance between actual decision-making and decision control preferences and its association with patient satisfaction. In this cross-sectional survey of advanced cancer patients referred to palliative care across 11 countries, we evaluated sociodemographic variables, Control Preference Scale, and satisfaction with the decisions and care. A total of 1490 participants were evaluable. Shared, active, and passive decision control preferences were 33%, 44%, and 23%, respectively. Passive decision control preferences (odds ratio, p value) was more frequent in India (4.34, <0.001), Jordan (3.41, <0.001), and France (3.27, <0.001). Concordance between the actual decision-making and decision control preferences was highest in the United States (k = 0.74) and lowest in Brazil (0.34). Passive decision control preference was significantly associated with (odds ratio per point, p value) better performance status (0.99/point, 0.017), higher education (0.64, 0.001), and country of origin (Brazil (0.26, <0.0001), Singapore (0.25, 0.0003), South Africa (0.32, 0.0002), and Jordan (2.33, 0.0037)). Passive decision control preferences were less common (23%) than shared and active decision control preference even among developing countries. Significant predictors of passive decision control preferences were performance status, education, and country of origin.

1 January 2012 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
Sriram YennuSriram Yennu
Sriram Yennu
BABradley Atkinson
Bradley Atkinson
JMJessica Masterson
Jessica Masterson
DHDavid Hui
David Hui
DUDiana Urbauer
Diana Urbauer
EBEduardo Bruera
Eduardo Bruera
Objectives: There are limited studies characterizing cancer-related symptoms in outpatient advanced prostate cancer patients. The aim of this retrospective study was to describe the impact of an outpatient palliative care (PC) consultation on symptoms in patients with advanced prostate cancer. Methods: We retrospectively reviewed the medical records of 55 consecutive patients with advanced prostate cancer seen in our institution's outpatient PC center. Information regarding demographics, disease status, Edmonton Symptom Assessment System (ESAS) scores, Eastern Cooperative Oncology Group (ECOG) Performance Status, laboratory data, and pharmacological interventions were analyzed. Results: The median age of the study's patients was 66 years old, with 73% Caucasian ethnicity. All patients had metastatic disease and 96% had received prior cytotoxic chemotherapy. The most frequently occurring symptoms upon presentation were pain, fatigue, and drowsiness (>50%). Pain and fatigue were also the most severe symptoms, each having median ESAS scores of 7 (on a 0–10 scale). We instituted a median of 3 pharmacological interventions per patient, with a median of 15 days to follow-up assessment. At follow-up, patients reported significant symptom improvements in pain, drowsiness, fatigue, depression, sleep, sense of well-being, and anxiety. Conclusions: Based on our preliminary data, we conclude that patients with advanced prostate cancer referred to PC experience severe and clinically significant symptoms. An outpatient PCconsultation is associated with significant symptom improvement in this subset of a distressed population. Future prospective studies are warranted to further describe symptom burden and the role for outpatient PC for advanced prostate cancer patients.